Ceruletide (Caerulein): frog-derived peptide that mimics the gut's "I'm full" hormone

What this is

Ceruletide (also written caerulein) is a small peptide originally isolated from the skin of the Australian green tree frog (Litoria caerulea) that mimics one of the body's own gut hormones — cholecystokinin (CCK). When released after a meal, CCK tells the gallbladder to contract, prompts the pancreas to pour out digestive enzymes, and relays a "full" signal to the brain via the vagus nerve. Ceruletide does all of this more potently than natural CCK at equivalent doses. It has been used clinically in Europe and Japan since the 1980s as a diagnostic agent for gallbladder and pancreatic function, and is a foundational research tool for studying CCK biology and acute pancreatitis. The stored sequence (QDY) is a platform shorthand; the actual peptide is a ten-residue chain (Pyr-Gln-Asp-Tyr(SO₃H)-Thr-Gly-Trp-Met-Asp-Phe) with a pyroglutamyl cap at the N-terminus, a sulfate group on the tyrosine residue essential for receptor activity, and a C-terminal amide — none of which are visible in the abbreviated stored sequence.

History

Ceruletide was first described around 1966 by Professor Vittorio Erspamer and colleagues, who identified it in extracts of dried Hyla caerulea frog skin on the basis of its blood-pressure-lowering properties (Keppel Hesselink 2020). The full decapeptide sequence was subsequently characterized as Pyr-Gln-Asp-Tyr(SO₃H)-Thr-Gly-Trp-Met-Asp-Phe-NH₂. Researchers quickly noted the striking resemblance between the C-terminal seven residues of ceruletide and the C-terminal octapeptide of cholecystokinin (CCK-8), explaining its potent CCK-like activity. Early in vivo experiments found ceruletide approximately three times as active as CCK purified from pig intestine. By the 1970s, the synthetic form (trade name Caeruletide) was being used in human pancreatic function studies. Since the 1980s it has been available in clinical practice as a parenteral solution — marketed as Cerulex in France, Takus in Germany, and registered under the trade name Tymtran in the United States — primarily as a diagnostic agent for characterising pancreas and gallbladder dysfunction (Keppel Hesselink 2020).

What it does

Ceruletide binds to CCK receptors in the gut and pancreas, triggering gallbladder contraction, stimulating pancreatic exocrine secretion (digestive enzymes and bicarbonate-rich fluid), and promoting gastrointestinal smooth muscle motility. These peripheral effects are also linked to a satiety signal: ceruletide produces a feeling of fullness by activating CCK receptors on vagal afferent nerve terminals in the abdomen, which relay the signal to the brainstem — not by acting directly on the brain (Smith and colleagues 1984). In human studies, low doses of ceruletide reduced solid food consumption in lean subjects; satiety effects in obese individuals were less consistent (Stacher 1985). Separately from its gut and satiety roles, ceruletide has shown analgesic properties in preclinical models and in a series of clinical investigations involving cancer pain, colic, and visceral pain conditions (Keppel Hesselink 2020). Its interaction with the opioid system is also documented: CCK receptor agonists, including ceruletide, modulate morphine-related effects in animal models, with CCK1 receptor activation opposing dependence-related behaviors (Zarrindast and colleagues 1995).

Evidence

• Human: Ceruletide reduced food intake in lean volunteers in controlled studies (Stacher 1985). In small clinical studies from the 1980s, intravenous infusions produced measurable analgesia in healthy volunteers and in patients with cancer pain, burn pain, and biliary colic (Keppel Hesselink 2020, reviewing Stacher 1982, Basso 1982, Dolecek 1983, Pardo 1984, Meyer-Lindau 1988). Its diagnostic use for pancreatic function testing and gallbladder stimulation was established in human studies during the 1970s.
• Animal: Supramaximal infusion of ceruletide induces acute edematous pancreatitis in rats and, with repeated dosing, necrotizing pancreatitis in mice — a model that has generated thousands of published papers on pancreatic pathophysiology. CCK1 receptor over-expression studies in rodents showed that ceruletide-class agonists oppose morphine dependence behaviors (Zarrindast and colleagues 1995).
• In vitro: Ceruletide stimulates amylase and lipase release from isolated pancreatic acinar cells through Gαq-coupled phospholipase C activation, IP₃-mediated calcium mobilization, and diacylglycerol signaling — without elevating cAMP. Its sulfated tyrosine residue is essential for receptor engagement; desulfated analogs show markedly reduced potency.

Known effects

• Gallbladder contraction and pancreatic enzyme secretion — diagnostic use, clinical (Keppel Hesselink 2020)
• Satiety / food intake reduction — human studies in lean subjects; inconsistent in obese (Stacher 1985)
• Analgesia — clinical case series and small controlled studies; mechanism involves CCK2 receptor signaling in the central amygdala (Keppel Hesselink 2020)
• Experimental pancreatitis induction — preclinical model (supramaximal dosing only)
• Modulation of opioid-related effects — preclinical; CCK1 agonism opposes morphine dependence (Zarrindast and colleagues 1995)

Safety signals

Across the clinical studies reviewed by Keppel Hesselink (2020), side effects at diagnostic and analgesic doses were described as infrequent and mild — headache, nausea, and transient abdominal colic, predominantly when infusion rate was too high. No serious adverse events were documented in the reviewed series. Supramaximal dosing (as used in pancreatitis animal models) is not a clinical use — at those concentrations, acinar cell injury is the intended experimental endpoint.

Regulatory status

• US: The Tymtran formulation (0.02 mg/mL injectable) is FDA-registered. Ceruletide carries ATC code V04CC04 (diagnostic agents — bile duct patency assessment).
• Europe: Marketed as Cerulex (France) and Takus (Germany) for diagnostic use. Currently manufactured in Italy by Pfizer Italia S.r.l. (Keppel Hesselink 2020).
• Research: Widely available as a research reagent from commercial suppliers under the names caerulein and ceruletide.
• WADA / doping: No listing identified.

Mechanism

Ceruletide is a full agonist at both CCK1 (CCKA) and CCK2 (CCKB) receptors, which are G-protein-coupled receptors. Binding activates Gαq, which stimulates phosphoinositide-specific phospholipase C to hydrolyze PIP₂ into IP₃ and diacylglycerol. IP₃ releases calcium from the endoplasmic reticulum of pancreatic acinar cells, driving exocytosis of zymogen granules and secretion of digestive enzymes. On vagal afferent neurons, CCK1 receptor activation transmits the satiety signal from gut to brainstem without requiring the peptide to cross the blood-brain barrier — peripheral administration inhibits food intake, while direct central (intraventricular) administration at the same dose does not (Smith and colleagues 1984). Analgesic effects appear to involve CCK2 receptor-mediated plasticity in the central amygdala, distinct from the opioid pathway but interacting with it; CCK1 receptor activation tends to oppose, and CCK2 receptor activation tends to facilitate, opioid-related behaviors in rodent models (Zarrindast and colleagues 1995; Keppel Hesselink 2020). The sulfated tyrosine at position 4 of the full sequence is critical — removal of the sulfate group substantially reduces receptor affinity for both CCK1 and CCK2.

Related peptides

• Cholecystokinin (CCK-8) — the endogenous octapeptide that shares the C-terminal Gly-Trp-Met-Asp-Phe-NH₂ motif with ceruletide and activates the same CCKAR pathway; ceruletide was modelled partly on its structure.
• Sincalide — a synthetic C-terminal octapeptide of CCK (CCK-8) used clinically for gallbladder stimulation and cholescintigraphy; pharmacologically closely related to ceruletide.